MA VICTORIA ESCARDA: Open Payments
NPI 1962883553 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,007 in 131 payments from 13 companies in 2025. Trend: 2023 $2,938 · 2024 $2,437 · 2025 $3,007
Food & beverage: $2,806Education: $201
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $564 |
| Otsuka America Pharmaceutical, Inc. | 17 | $436 |
| Teva Pharmaceuticals USA, Inc. | 11 | $374 |
| Neurocrine BioSciences, Inc. | 12 | $357 |
| E.R. Squibb & Sons, L.L.C. | 13 | $286 |
| ABBVIE INC. | 11 | $227 |
| Alkermes, Inc. | 10 | $212 |
| Janssen Pharmaceuticals, Inc | 7 | $149 |
| Indivior Inc. | 4 | $123 |
| Lundbeck LLC | 6 | $102 |
Products named: CAPLYTA, REXULTI, INGREZZA, COBENFY, VRAYLAR, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
